The Pulmonary Fibrosis Foundation (PFF) recently announced that the number of scientific poster presentations on idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILD) to be displayed at the upcoming PFF Summit 2015: From Bench to Bedside in Washington, D.C., reached a record. The PFF Summit 2015: From…
Help raise awareness for this serious and devastating disease. Learn more about Pulmonary Fibrosis: http://bit.ly/1lfMsiZ…
Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was…
1. Lung Stem Cell Spheroids Could Offer Cheap, Rapid Pulmonary Fibrosis Therapy 2. Genentech to Help Lead Pulmonary Fibrosis Foundation Programs 3. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015…
The Pulmonary Fibrosis Foundation (PFF) recently announced in a press release a five-year collaboration with Boehringer Ingelheim to support PFF programs dedicated to the improvement of the clinical outcome in patients with pulmonary fibrosis (PF), increase awareness about the disease, and offer advance care, disease education and…
In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13, was…
“Watch this video for some facts on Idiopathic Pulmonary Fibrosis.” Read more about IPF: http://bit.ly/1QiRmr3…
The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role of Founding…
Esbriet is an anti-inflammatory and anti-fibrotic drug that reduces inflammation and fibrosis simultaneously. Learn more: http://bit.ly/Esbriet Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This…
While the therapy was approved for use in 2014 in the US, Japan was the first country to approve its commercial use in 2008, followed by India in 2010, Europe in 2011, and China in 2013. Because IPF is considered a rare condition, this drug was…
Get regular updates to your inbox.
